LEMONIS MARCUS 4

What Happened
Marcus Lemonis, Executive Chairman & CEO (and director) of Bed Bath & Beyond, was credited with 424,300 performance shares on Feb 4, 2026 after the compensation committee determined those shares were earned for fiscal 2025. The filing reports the performance-share award as a derivative grant (424,300 shares @ $0.00; reported value $424). The report also records a prior pro‑rata distribution of 45,615 warrants dated Oct 7, 2025 (reported value $46).

Key Details

• Transaction dates: Feb 4, 2026 (performance shares); Oct 7, 2025 (warrant distribution). Filing date: Feb 6, 2026. Filing appears timely.
• Reported amounts: 424,300 performance shares (derivative, reported $424); 45,615 warrants (reported $46).
• Exercise/strike: Each warrant (from Oct 7, 2025 distribution) entitles holder to buy one share at $15.50 per warrant.
• Shares owned after transaction: not disclosed in this Form 4 filing.
• Footnotes: F1 — performance shares are contingent rights to receive common stock and will vest in three equal installments (Mar 10, 2026; Mar 10, 2027; Mar 10, 2028) subject to continued service and satisfaction of performance criteria. F2 — warrants were a pro‑rata distribution exempt from immediate Section 16 reporting.

Context
These are compensation-related derivative awards, not open‑market purchases or sales. The performance shares are contingent and will only convert to stock if performance and service conditions are met; the warrants give the right to buy stock at $15.50. Such awards reflect compensation outcomes and do not by themselves indicate an immediate insider purchase or sale.